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Abstract 
Alcohol consumption is associated with higher risk of breast cancer (BC); however, the biological 
mechanisms underlying this association are not fully elucidated, particularly the extent to which this 
relationship is mediated by sex hormone levels. Circulating concentrations of estradiol, testosterone, 
their free fractions and sex‐hormone binding globulin (SHBG), were examined in 430 incident BC 
cases and 645 matched controls among alcohol‐consuming postmenopausal women nested within 
the European Prospective Investigation into Cancer and Nutrition. Mediation analysis was applied to 
assess whether individual hormone levels mediated the relationship between alcohol intake and BC 
risk. An alcohol‐related hormonal signature, obtained by partial least square (PLS) regression, was 
evaluated as a potential mediator. Total (TE), natural direct and natural indirect effects (NIE) were 
estimated. Alcohol intake was positively associated with overall BC risk and specifically with estrogen 
receptor‐positive tumors with respectively TE = 1.17(95%CI: 1.01,1.35) and 1.36(1.08,1.70) for a 1‐
standard deviation (1‐SD) increase of intake. There was no evidence of mediation by sex steroids or 
SHBG separately except for a weak indirect effect through free estradiol where NIE = 1.03(1.00,1.06). 
However, an alcohol‐related hormonal signature negatively associated with SHBG and positively 
with estradiol and testosterone was associated with BC risk (odds ratio [OR] = 1.25 [1.07,1.47]) for a 
1‐SD higher PLS score, and had a statistically significant NIE accounting for a mediated proportion of 
24%. There was limited evidence of mediation of the alcohol‐BC association by individual sex 
hormones. However, a hormonal signature, reflecting lower levels of SHBG and higher levels of sex 
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Introduction 
Breast cancer (BC) is the most frequent type of cancer accounting for nearly a quarter of all cancers 
in women worldwide with about 2.08 million incidents BC cases diagnosed in 2018.1 BC incidence is 
expected to continue rising with increases in obesity, reductions in fertility and aging of the 
population, in particular in developing countries.2 BC is a multifactorial disease and its etiology 
includes dietary, lifestyle, hormonal and reproductive risk factors.3 Among these, alcohol intake has 
been consistently associated with higher BC risk and has been classified by the International Agency 
for Research on Cancer (IARC) as a carcinogen (Group 1).4 The evidence is considered strong both in 
premenopausal and postmenopausal women,5-8 as confirmed by in a comprehensive analysis by the 
World Cancer Research Fund (WCRF).9 
 
A positive dose–response association between alcohol intake and BC risk, consistently across 
hormonal receptor status, was shown in a study based on 11,576 incident BC cases within the 
European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.10 Little is known on the 
mechanisms through which alcohol exerts its carcinogenic effect during BC development, yet 
accumulating evidence suggests that the association between alcohol intake and breast 
carcinogenesis may be partly mediated through endogenous sex steroids.11-15 Estrogens and 
androgens are well‐known activators of cellular proliferation and are associated with an increased 
BC risk.15 Findings from the EPIC study and the Endogenous Hormones and Breast Cancer 
Collaborative Group supported the association between elevated prediagnostic serum 
concentrations of estrogens, androgens and low serum levels of sex hormone binding globulin 
(SHBG) and higher postmenopausal BC risk.16-18 It has been suggested that alcohol consumption 
increases the concentrations of sex steroids in serum in both premenopausal and postmenopausal 
women.15 In EPIC, higher concentrations of androgens including testosterone and free testosterone, 
and lower concentrations of SHBG were observed in postmenopausal women who consumed more 
than 25 g/day of alcohol (i.e., 2 glasses) compared to women who were nonconsumers.19 A review 
suggested that estrogens could mediate the relationship between alcohol and BC as alcohol elevates 
concentrations of circulating oestrogens.15 In postmenopausal women, nearly 100% of estrogens 
are synthesized from aromatization of androgens in peripheral tissues, with SHBG regulating their 
circulating concentrations and that of their free fractions.20 
 
To the best of our knowledge, only one study conducted within the Women's Health Initiative has 
explored a causal pathway from alcohol to postmenopausal BC operating through serum estrogen, 
but no significant evidence was found.21 
 
Here, we examine whether estradiol, testosterone, their free fractions and SHBG, as well as a 
composite hormonal signature, mediated the relationship between alcohol intake and 
postmenopausal BC in a nested case–control study within EPIC, among alcohol drinkers. 
 
Materials and Methods 
The EPIC study 
EPIC is a multicenter prospective cohort designed to investigate the associations of diet, lifestyle, 
environmental and metabolic factors with cancer and other disease outcomes. Over 360,000 women 
and 150,000 men aged 20–85 years were recruited between 1992 and 2000 from 23 centers 
spanning 10 European countries: Denmark, France, Germany, Greece, Italy, Norway, Spain, Sweden, 
The Netherlands and the United Kingdom.22 The rationale, study design and methods of the EPIC 
study have been extensively described.22-24 Biological samples were collected at recruitment prior 
to disease onset in approximately 80% of the cohort and were stored at IARC (Lyon, France) in 
−196°C liquid nitrogen for all countries, except from Denmark (nitrogen vapor, −150°C) and Sweden 
(freezers, −80°C) where samples were stored locally. All participants gave their written informed 
consent to use their questionnaire data and biological samples for future analyses. 
 
Exposure assessment 
During the enrolment period, information on sociodemographic characteristics including education, 
occupational and recreational levels of physical activity, tobacco smoking, medical and reproductive 
history, exogenous hormone use, anthropometric measures as well as alcohol consumption habits 
was gathered using lifestyle questionnaires. Dietary intake over the 12 months was assessed at 
baseline using validated country‐specific dietary questionnaires (self‐administered, food frequency 
questionnaires, semiquantitative or interviewer‐performed) designed to specifically capture local 
habits with high compliance as detailed elsewhere.22-24 Baseline alcohol intake was calculated from 
the number of glasses of beer and/or wine, cider, sweet liquors, fortified wines, distilled spirits 
consumed per day or week in the year preceding recruitment. The individual average daily alcohol 
intake, expressed in grams per day (g/day), was computed based on the standard glass volume and 
ethanol content as the sum of the ethanol content of all alcoholic beverages consumed obtained 
through country‐specific food composition tables per alcoholic beverage type. This calculation was 
done based on data collected through 24‐hr dietary recalls from a subgroup of the cohort containing 
detailed information on alcohol intake distribution during the day in relation to main meals.25, 26 
 
Ascertainment of cancer outcome 
Incident BC cases were identified through record linkage with regional cancer and pathology 
registries with the exception of Naples (Italy), Germany, Greece and France where a combination of 
methods was employed including: cancer and pathology registries, health insurance records, active 
follow‐up through direct contact with study subjects or next of kin, and collection of clinical records. 
Vital status was ascertained from municipal, regional or national‐level mortality registries. For our 
study, the closure date was the last date of complete follow‐up, both for cancer incidence and vital 
status, ranging from 2003 to 2006, depending on each EPIC study center.16, 22, 27-29 All the self‐
reported BC cases were systematically verified from clinical and pathologic records. Cancer incidence 
data were classified according to the International Classification of Diseases for Oncology (ICD‐O), as 
first primary invasive BC, ICD‐O codes C50. Information on hormone receptor status (estrogen and 
progesterone) as well as the laboratory methods and quantification descriptions used to determine 
the receptor status, were collected by the EPIC centers and criteria were retained to harmonize 
positive receptor identification across centers.28 
 
The nested case–control study 
The current study is based upon data available from two nested case–control studies within EPIC on 
postmenopausal BC risk and endogenous hormone levels (“study phase 1”27 and “study phase 
2”28). Norway and Sweden were not included in these analyses either because a blood serum 
sample was not available or because independent studies were being completed on BC risk. In both 
study phases, postmenopausal women were included. Postmenopausal women were defined as 
women who had no menstruations in the 12 months preceding study enrolment, or were older than 
55 years of age if the menstrual cycle information was not available, or who had undergone a 
bilateral oophorectomy. Only women with available blood samples who were not using any 
menopausal hormone therapy at the time of blood collection (as the use of exogenous hormones 
influences the endogenous concentrations and some may be the same as endogenous), and who did 
not have any prevalent cancer at baseline (with the exception of nonmelanoma skin cancer) were 
included into the study. For each case, up to two controls with a blood sample available were chosen 
at random among appropriate risk sets consisting of all postmenopausal cohort members alive and 
free of cancer at the time of diagnosis of the case. This was done using an incidence density 
sampling protocol allowing the inclusion of subjects who became a case later in time, while each 
control could be sampled more than once.28 Controls were matched to the cases on study 
recruitment center, age at blood donation (±6 months), follow‐up time since blood donation (±3 
months), time of the day of blood collection (±1 hr), and fasting status (<3 hr, 3–6 hr, >6 hr). 
Analyses were also conducted stratifying on estrogen receptor (ER) status. Over the two study 
phases, there were 798 BC and 1,294 matched controls with 387 cases being estrogen receptor 
positive (ER+) tumors, 153 estrogen negative tumors (ER−) and 258 with unknown hormonal 
receptor status (estrogen and/or progesterone). After excluding case sets in which the case or her 
control(s) were nondrinkers (daily intake <0.1 g/day), the final study sample included 430 cases and 
645 matched controls with 218 ER+ (62% from “study phase 1” and 38% from “study phase 2”), 105 
ER− (27% from “study phase 1” and 73% from “study phase 2”) and 107 with unknown hormonal 
receptor status (estrogen and/or progesterone). The ethical review boards of the participating 
institutions/countries/study centers and the International Agency for Research on Cancer (IARC) 
approved each of the two phases of the study. 
 
Hormone concentrations 
For all women in “study phase 1”, hormone measurements of estradiol (pmol/l), testosterone 
(nmol/l), and SHBG (nmol/l) were performed at IARC, while for “study phase 2” they were 
performed at the German Cancer Research Center (DKFZ). The same assay methods were used 
whenever possible in the two phases of the study, as detailed elsewhere.16, 28 Cases and their 
matched controls were analyzed within the same analytical batch and laboratory technicians were 
blinded to the case–control status of the study participants. Serum concentrations of free estradiol 
(pmol/l) and free testosterone (nmol/l) were computed from mass action law equations using 
absolute concentrations of each sex steroid and SHBG assuming a constant concentration of 43 g/l 
for albumin.28, 30, 31 
 
Statistical analyses 
In all analyses, baseline alcohol intake (g/day), sex hormones and SHBG levels were log‐transformed 
to normalize their distributions [ln(alcohol+1)]. In addition, for the sex hormones and SHBG, 
residuals on center were computed to account for variability that lies in the phase of study, 
distribution across batches of each sex steroid, and the differences of study protocols for sample 
collection and preparation including treatment and sample handling, for example, thaw–freeze 
cycles. The residuals were calculated for each biomarker in univariate linear regression models. 
Geometric means for sex steroids and SHBG in alcohol consumers as well as 2.5th and 97.5th 
quantiles were computed for cases and controls by study phase. The difference in hormone and 
SHBG levels between cases and controls was assessed through two‐sample t‐tests computed on the 
log‐transformed concentrations. 
 
Partial least square analysis 
With the aim of deriving a hormonal signature associated with alcohol intake, we applied partial 
least squares (PLS) analysis, a multivariate dimension‐reduction method that generalizes features of 
principal component analysis with those of multiple linear regression.32 The mathematical and 
computational details of the PLS method have been thoroughly described in our previous studies 
within EPIC.33, 34 In brief, one PLS factor was retained after performing PLS analysis only among 
controls in the subset of alcohol consumers and a linear combination of the response variables (i.e., 
estradiol, testosterone and SHBG), was extracted that had maximum covariance with the predictor 
variable (alcohol intake). Using the loadings derived from the analysis, that is, the coefficients 
quantifying the contribution of each hormone to the PLS factor, the PLS score was computed and 
subsequently extrapolated to the cases. The score was tested as a composite mediator in the 
alcohol‐BC association using mediation analysis as described below. Similarly, a PLS sensitivity 
analysis was performed including free fractions of estradiol and testosterone from the response set 
as both these free fractions were computed from SHBG and estradiol or testosterone. The PLS score 
was calculated as formerly detailed and successively used in a mediation analysis. As the results 
were virtually unchanged, we did not report the results for this sensitivity analysis. 
 
Alcohol and BC association 
The association between alcohol intake and BC risk was first evaluated in multivariable conditional 
logistic regression models within the total nested case–control study. Since no statistically significant 
association was found for a one‐standard‐deviation (1‐SD) higher log‐transformed alcohol intake and 




The mediating role of each sex steroids and SHBG (mediator) in the association between alcohol 
consumption (exposure) and BC (outcome) was examined and mediating effects were assessed 
separately for each of the considered mediators, and for their composite signature, among alcohol 
consumers. Estimates of the natural direct effect (NDE), the natural indirect effect (NIE), the total 
effect (TE) as well as the effect of the mediator adjusted for alcohol, that is, the exposure, and for 
confounding variables were computed using a counterfactual approach adapted to dichotomous 
outcomes.35 Formulae from VanderWeele and Vansteelandt36 were adapted to accommodate 
continuous exposures and use of conditional logistic regression models for our matched study 
design. In brief, two models were specified to obtain NDE and NIE and the odds ratio (OR) for the 
mediator effect adjusted for the exposure. In the outcome model, the exposure and the mediator 
were related to the BC indicator in a conditional logistic regression. In models for each mediator of 
interest, the mediator was linearly regressed on the exposure. This was done only on the subset of 
controls to account for the nested case–control design.37 The TE was obtained from a conditional 
logistic regression relating to alcohol intake to BC risk. The formulae detailing how to obtain 
estimates and their associated 95%CI and p‐value as well as the notations used have been 
extensively detailed in our previous work.33 Assuming the outcome was rare, we computed the 
proportion mediated which is measure defined on the risk difference (RD) scale and captures the 
importance of the mediating pathway.37 Based on the estimated ORs, this quantity was calculated 
using the following formula: urn:x-wiley:00207136:media:ijc32324:ijc32324-math-0001 36 Since 
mediation analysis was applied to the nested case–control study restricted to alcohol consumers, 
the interpretation of the causal effects is for an increase of one standard deviation in the exposure 
(log transformed alcohol intake) among alcohol consumers. All models were adjusted for a list of 
potential confounders including body mass index (BMI, continuous), age at menopause (continuous) 
and the following categorical variables: smoking status (never, former, current, unknown), education 
level (none, primary school, technical/professional school, secondary school, longer education 
including university degree, unknown/unspecified), physical activity index (inactive, moderately 
inactive, moderately active, active, unknown), use of menopausal hormone therapy (ever vs. never), 
use of contraceptive pill (ever vs. never), age at first full‐term pregnancy (nulliparous, <23 years, 24–
25 years, 26–28 years, >29 years), number of full term pregnancies (nulliparous, 1 full‐term birth, 2 
full‐term births, 3 full‐term births, 4 or more full‐term births), and age at menarche (<12 years, 
12 years, 13 years, 14 years, >14 years). The mediator model was additionally adjusted for study 
phase (phase 1 vs. phase 2). Interactions between the exposure and each of the confounders were 
tested both in the outcome model and in the mediator model among controls, with an additional 
test for exposure‐mediator interaction in the former and a term testing interaction between 
exposure and age at blood collection in the latter. None of the interactions were statistically 
significant and therefore were not included the final mediation analyses. 
 
All statistical tests were two‐sided, p‐values <0.05 were considered statistically significant. All 
analyses were performed using the R statistical software, with the package “plsgenomics” used for 
PLS analysis and mediation computed with an in‐house macro. 
 
Results 
The study population characteristics by case–control status are presented in Table 1 for the case‐
sets of alcohol consumers that were examined in our study. Overall, cases had a higher average 
alcohol intake compared to controls (11.3 vs. 9.5 g/day) and a higher total energy intake (1,970 vs. 
1,919 kcal/day). Supporting Information Table S1 shows the characteristics of the whole population 
of the nested case–control study. Hormone concentration levels for the study population at baseline 
restricted to drinker case‐sets are shown in Supporting Information Table S2 by study phase. 
Concentrations of testosterone and free testosterone were significantly higher in cases than in 
controls in “study phase 2”, whereas concentrations of estradiol and its free fraction were 
significantly higher in cases than in controls in “study phase 1”. Additionally, the concentration 
values for estradiol were on average higher in “study phase 1” than in “study phase 2” (respectively 
99.1 and 89.2 for cases and controls vs. 45.0 and 41.7) likely due to differences in assays between 
phases. 
 
Table 1. Baseline characteristics of the study population of the EPIC nested case–control study on 
postmenopausal BC—case‐sets where both cases and controls are alcohol consumers at baseline 
(>0.1 g/day) 
Characteristics1 Cases Controls 
Number of subjects 430 645 
Case‐sets with ER‐positive tumors 218 318 
Case‐sets with ER‐negative tumors 105 126 
Age at blood collection (years) 59.9 (50.5,71.3) 60.1 (50.9,71.4) 
Height (cm) 162.0 (150.5,174.6) 161.4 (149.1,174.0) 
Weight (kg) 69.0 (50.7,98.4) 66.6 (49.2,90.5) 
BMI (kg/m2) 26.3 (19.7,37.1) 25.6 (19.3,35.5) 
Total energy intake (kcal/day) 1970.4 (1,117.6,3,063.4) 1919.1 (1,077.7,3,095.9) 
Alcohol intake at recruitment (g/day) 11.3 (0.20,44.9) 9.5 (0.20,42.5) 
Age at menopause (years) 49.3 (38.0,57.0) 48.9 (36.2,56.9) 
Years between blood donation and diagnosis (years) 3.7 (0.6,9.5) – 
Age at menarche   
<12 years 54 (12.6) 69 (10.7) 
12 years 85 (18.9) 128 (19.8) 
13 years 91 (21.2) 140 (21.7) 
14 years 104 (24.2) 153 (23.7) 
>14 years 86 (20.0) 145 (22.5) 
Unknown 10 (2.3) 10 (1.6) 
Age at first full‐term pregnancy   
Nulliparous 69 (16.0) 88 (13.6) 
<23 years 118 (27.4) 198 (30.7) 
24–25 years 62 (14.4) 115 (17.8) 
26–28 years 96 (22.3) 141 (21.9) 
>29 years 85 (19.8) 103 (16.0) 
Use of contraceptive pill2   
Ever 175 (40.7) 269 (41.7) 
Never 248 (57.7) 374 (58.0) 
Unknown 7 (1.6) 2 (0.3) 
Use of hormonal menopause therapy2   
Ever 87 (20.2) 142 (22.0) 
Never 342 (79.6) 502 (77.8) 
Unknown 1 (0.2) 1 (0.2) 
Physical activity levels   
Active 94 (21.9) 134 (20.8) 
Moderately active 71 (16.5) 123 (19.1) 
Moderately inactive 162 (37.7) 221 (34.3) 
Inactive 102 (23.7) 164 (25.4) 
Unknown 1 (0.2) 3 (0.5) 
Smoking status   
Never 241 (56.0) 345 (53.5) 
Former 116 (27.0) 175 (27.1) 
Current smoker 71 (16.5) 121 (18.8) 
Unknown 2 (0.5) 4 (0.6) 
Fasting status at the time of blood collection   
No (<3 hr) 240 (55.8) 360 (55.8) 
In between (3–6 hr) 86 (20.0) 116 (18.0) 
Yes (>6 hr) 92 (21.4) 145 (22.5) 
Unknown 12 (2.8) 24 (3.7) 
Education level   
None 4 (0.9) 9 (1.4) 
Primary school completed 158 (36.7) 238 (36.9) 
Secondary school 69 (16.0) 107 (16.6) 
Technical/professional school 110 (25.6) 167 (25.9) 
Longer education (including university degree) 58 (13.5) 72 (11.2) 
Unknown 31 (7.2) 52 (8.1) 
1 Values are presented as means and 2.5th and 97.5th percentiles in parentheses for continuous 
variables and as frequencies and percentages in parentheses for categorical variables. 
2 Women included in the study were not using any form of exogenous hormones at recruitment. 
In our final study population, alcohol intake was statistically significantly associated with higher BC 
risk with TE OR = 1.17(1.01,1.35) for a 1‐SD higher log‐transformed alcohol intake (Table 2). The 
association was stronger in ER+ tumors with TE OR = 1.36(1.08,1.70, n cases = 218). There was no 
association found for ER‐ BC (TE OR = 1.29[0.87, 1.91, n cases = 105]). A positive association with BC 
risk overall and for ER+ BC was observed for 1‐SD increase in log‐transformed hormones with 
OR = 1.38(1.12,1.70) and 1.83(1.28,2.63) for estradiol, 1.32(1.08,1.61) and 1.51(1.10,2.08) for free 
estradiol and 1.21(1.03,1.41) and 1.45(1.13,1.87) for testosterone, respectively. There was an 
inverse association between SHBG and ER− BC risk (Supporting Information Table S3). 
 
Table 2. Odds ratio and 95% confidence intervals (95%CI) for the total effects (TE) of alcohol on 
postmenopausal BC for 1‐SD increase in log‐alcohol intake 
Tumor type n cases/n controls TE (95%CI)1 
In total nested case–control study 
Overall BC 798/1294 1.03 (0.93,1.14) 
ER‐positive 387/612 1.04 (0.89,1.21) 
ER‐negative 153/193 1.07 (0.80,1.45) 
In nested case–control study restricted to alcohol consumers case‐sets (>0.1 g/day) 
Overall BC 430/645 1.17 (1.01,1.35) 
ER‐positive 218/318 1.36 (1.08,1.70) 
ER‐negative 105/126 1.29 (0.87,1.91) 
1 Statistically significant TEs are displayed in bold font. 
Results from individual mediation analyses are presented in Table 3 with estimates for the direct and 
indirect effects. In the ER+ subset, the NDE estimates for the direct association of alcohol with BC 
risk considering estradiol, free estradiol, testosterone, free testosterone and SHBG as the mediator, 
were statistically significant with NDE = 1.35(1.07,1.70) 1.34(1.07,1.69), 1.30(1.02,1.64), 
1.33(1.05,1.68) and 1.35(1.08,1.70), respectively (Table 3). None of the NIE estimates were 
statistically significant suggesting that the four sex steroids and SHBG did not mediate the alcohol 
and BC association individually (Table 3). However, the NIE was borderline significant for free 
estradiol (1.03 [1.00,1.06]) suggesting a weak mediation by free estradiol corresponding to a 
mediated proportion of 19%. 
 
Table 3. Results from the mediation analyses in case‐sets of alcohol consumers (>0.1 g/day), with 
ORs and their associated 95%CIs for the natural direct effect (NDE) and the natural indirect effect 
(NIE) using residuals based on center for the log‐transformed hormone levels 
Hormone NDE (95%CI) NIE (95%CI) % mediated—RD scale1 
Overall BC 
Estradiol 1.15 (1.00,1.33) 1.02 (0.99,1.04) 13 
Free estradiol 1.15 (0.99,1.33) 1.03 (1.00,1.06) 19 
Testosterone 1.12 (0.96,1.30) 1.02 (1.00,1.04) 16 
Free testosterone 1.13 (0.98,1.31) 1.01 (0.99,1.03) 8 
SHBG 1.16 (1.00,1.34) 1.02 (0.99,1.05) 13 
ER‐positive 
Estradiol 1.35 (1.07,1.70) 1.06 (0.98,1.14) 19 
Free estradiol 1.34 (1.07,1.69) 1.06 (0.99,1.13) 19 
Testosterone 1.30 (1.02,1.64) 1.00 (0.95,1.05) 0 
Free testosterone 1.33 (1.05,1.68) 1.00 (0.98,1.01) 0 
SHBG 1.35 (1.08,1.70) 1.00 (0.96,1.05) 0 
ER‐negative 
Estradiol 1.31 (0.88, 1.95) 1.01 (0.97,1.06) 4 
Free estradiol 1.31 (0.86,2.00) 1.03 (0.95,1.10) 11 
Testosterone 1.25 (0.83,1.87) 1.01 (0.98,1.04) 5 
Free testosterone 1.18 (0.76,1.82) 1.04 (0.96,1.13) 21 
SHBG 1.19 (0.77,1.84) 1.08 (0.97,1.22) 33 
Bold values indicating statistically significant findings. In the mediation analysis, the exposure was 
the log‐transformed alcohol at baseline, the mediator was in turn each one of the log‐transformed 
hormones (residuals on center), and the outcome was postmenopausal BC (subtypes listed above). 
The outcome models were computed through conditional logistic regressions. The mediator models 
were linear and additionally adjusted for phase of study. All models were adjusted for BMI 
(continuous), age at menopause (cont.), smoking status (categorical), education level (cat.), physical 
activity index (cat.), use of exogenous hormones (ever vs. never), use of pill (ever vs. never), number 
of full‐term pregnancies (cat.), age at full term pregnancy (cat.) and age at menarche (cat.). Cases 
and controls were matched on study recruitment center, age at blood collection (±6 months), time 
of the day at blood collection (±1 hr), fasting status (<3 hr, 3–6 hr, >6 hr) and study phase (1 or 2). 
1 NDE and NIE, their 95%CIs and proportion mediated on the RD scale are computed from formulae 
as detailed in Materials and Methods. ORs are expressed for an increase in one standard deviation of 
the residuals on center of the log‐transformed hormone variable. The NDE and NIE are expressed for 
an increase in one standard deviation of the log‐transformed alcohol intake. 
PLS analysis provided a composite signature of estradiol, testosterone and SHBG, as the first PLS 
factor, with positive loadings for estradiol (0.007) and testosterone (0.070) and a high negative 
loading for SHBG (−0.141; Supporting Information Table S4). An 1‐SD increase in the PLS score was 
associated with a higher BC risk with OR = 1.23 (1.05,1.43) and statistically significantly mediated the 
association between alcohol intake and overall BC risk with NIE = 1.04(1.01,1.07), accounting for a 
mediated proportion of 24% of the TE (Table 4). For ER+ and ER− BC subtypes, the hormonal 
signature did not mediate the alcohol‐BC association as the NIE, corresponding to a proportion 
mediated of 12 and 36%, were not statistically significant. The identified signature was however 
associated with high ER− risk with OR = 1.69(1.03,2.69) (Table 4). 
 
Table 4. Results from the mediation analyses: OR for the association between the PLS factor and 
postmenopausal BC and NDE and NIE and their respective 95%CI (analysis in case‐sets of alcohol 
consumers (>0.1 g/day) 
OR (95%CI) NDE (95%CI) NIE (95%CI) % mediated—RD scale1 
Overall BC 1.23 (1.05,1.43) 1.14 (0.98,1.32) 1.04 (1.01,1.07) 24 
ER positive 1.20 (0.95,1.51) 1.33 (1.06,1.67) 1.04 (0.99,1.09) 12 
ER negative 1.67 (1.03,2.69) 1.15 (0.75,1.75) 1.07 (0.97,1.19) 36 
Bold values indicating statistically significant findings. In the mediation analysis, the exposure was 
the log‐transformed alcohol at baseline, the mediator was the PLS factor computed using log‐
transformed residuals on center of estradiol, testosterone and SHBG, and the outcome was 
postmenopausal BC (subtypes listed above). The outcome models were computed through 
conditional logistic regressions. The mediator models were linear and additionally adjusted for phase 
of study. All models were adjusted for BMI (continuous), age at menopause (cont.), smoking status 
(categorical), education level (cat.), physical activity index (cat.), use of exogenous hormones (ever 
vs. never), use of pill (ever vs. never), number of full‐term pregnancies (cat.), age at full term 
pregnancy (cat.) and age at menarche (cat.). Cases and controls were matched on study recruitment 
center, age at blood collection (±6 months), time of the day at blood collection (±1 hr), fasting status 
(<3 hr, 3–6 hr, >6 hr) and study phase (1 or 2). 
1 NDE and NIE, their 95%CIs and proportion mediated on the RD scale are computed from formulae, 
see Materials and Methods. ORs are expressed for an increase in one standard deviation of the PLS 
hormonal signature score. The NDE and NIE are expressed for an increase in one standard deviation 
of the log‐transformed alcohol intake. 
Discussion 
In our study restricted to alcohol consumers, a candidate mechanism of the association between 
alcohol intake and postmenopausal BC development was investigated with mediation analysis. 
Overall, there was limited evidence that this association was mediated by individual sex‐hormone 
levels with a weak mediation by free estradiol, however, a composite score summarizing information 
from the individual hormones and SHBG showed that 24% of the relationship between alcohol and 
BC risk is mediated by a hormonal signature negatively associated with SHBG and positively related 
to sex steroids. 
 
Alcohol is an established risk factor for BC,4, 9 both in premenopausal and postmenopausal 
women.6, 38 Evidence from a reanalysis of 53 epidemiological studies suggested that the relative 
risk of BC increased linearly by 7% for each additional 10 g/day intake of alcohol (unit of alcohol as 
defined by WHO).39 A dose–response association was observed in EPIC, irrespective of beverage 
type, with a higher risk attaining 25% (17–35%) for the highest intakes compared to moderate 
alcohol use (from 0.1 to 5 g/day).10 
 
Despite this, the biological pathways that link alcohol with BC development are not well delineated. 
Hormones and SHBG are involved in complex biological pathways that regulate a host of metabolic 
functions.20, 40 It had previously been suggested that sex‐hormones could be involved in the 
underlying mechanism of the alcohol and BC association.41-43 Several controlled feeding studies44, 
45 and observational studies14, 17, 19, 46 reported associations between alcohol intake and 
increased sex‐hormone blood concentrations in both premenopausal and postmenopausal women. 
Compared to nondrinkers, concentrations of estrone, estradiol and dehydroepiandrosterone sulfate 
were higher in women consuming more than 25 g/day of alcohol in a cross‐sectional study in EPIC.14 
Findings of similar magnitude were reported in a study of 1,291 postmenopausal controls from a 
nested case–control study in EPIC19 with 10–20% larger levels of testosterone and free testosterone 
and 15% lower SHBG concentrations in alcohol consumers compared to nondrinkers. Similar 
associations were reported in a recent cross‐sectional analysis examining BC risk factors including 
alcohol and circulating sex hormones measured in over 6,000 postmenopausal controls from 13 
prospective studies.17 
 
The current study is the second of its kind to explore statistical mediation by sex steroids of the 
alcohol‐BC relation. Previously, the mediating role of estradiol was examined in a case–cohort study 
with 600 cases (of which 401 ER+ and 163 ER−) in the Women's Health Initiative, where no indirect 
effect was observed suggesting no evidence for alcohol effect through estradiol, although a 
significant association between alcohol and BC risk overall and in ER+ tumors in postmenopausal 
women was reported.21 Our study had similar findings in terms of weak evidence of mediation 
through estradiol, and a strong association of alcohol intake with ER+ tumors. However, it expanded 
on the latter study by exploring the mediating role of free estradiol, testosterone, free testosterone 
and SHBG in addition to a hormonal signature. 
 
Strengths of this analysis include the use of harmonized standardized dietary questionnaires which 
were used to estimate alcohol at baseline. Furthermore, we developed an alcohol‐driven hormonal 
signature that was associated with BC risk and was robust to exclusion of free fractions of estradiol 
and testosterone from the PLS analysis. Our analyses focused on alcohol consumers, as baseline 
alcohol non‐drinkers may be more health‐conscious, may be former heavy drinkers or participants 
with underlying disease, thus potentially introducing concerns related to reverse causation and, 
particularly, exposure misclassification. The BC nested case–control study was relatively large in 
sample size, as it combined two successive rounds of acquisitions of sex steroids in EPIC. 
 
Nevertheless, our study had limitations, among which the generally low alcohol intake of EPIC 
women, ~8 g/day on average with 80% below 15 g/day,10 but also among the participants of the BC 
nested case–control study ~10 g/day, which may limit the generalizability of our findings to 
populations with different alcohol consumption patterns. Another aspect pertains to a key 
assumption in mediation analysis, which requires a temporal ordering between exposure, mediator 
and outcome. In our study, alcohol was assessed at baseline at the same time of biological samples’ 
collection, estimating participants’ alcohol intakes over the 12 months preceding enrolment, and 
endogenous hormones were measured in a single blood sample from each woman reflecting a 
limited time‐frame. Although alcohol intake measurements indicated relatively high validity,24 and 
androgens, estrogens and SHBG concentrations in postmenopausal women show good 
reproducibility over time,47-49 both exposure and the mediators examined in our study may be 
subject to measurement errors. Under non‐differential measurement error with a normally 
distributed mediator, the bias of the NIE is toward the null and if direct and indirect effects are in the 
same direction, the bias of the NDE is away from the null.50 This may have contributed to an 
underestimation of the indirect effects and an overestimation of the direct effects in our study, 
resulting in a lower mediated proportion and possibly partially explaining the lack of mediation 
observed for sex steroids when examined separately. Finally, in our study, different 
radioimmunoassays were used to measure estradiol between phase 1 and phase 2.28 For this 
reason, estradiol concentrations displayed between‐studies variations, which we have tried to 
account for by adjusting for phase of study in the exposure‐mediator models. 
 
Conclusion 
Our findings suggested that alcohol intake was associated with higher postmenopausal BC risk in 
alcohol consumers, overall and for ER+ tumors, with limited evidence of mediation by sex steroids, 
when examined individually. However, the hormonal signature mediated about 24% of the alcohol‐
BC association, suggesting that any potential mechanism of sex‐steroids in the alcohol and BC 
relationship is likely to involve an interplay of hormones, beyond the action of single hormonal 
levels. Future replication of these findings is needed, possibly in populations with larger amounts of 
alcohol intake and larger sample size. Finally, our results suggest that sex hormones play a minor 
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